ANIX
ACHAT TOTAL: 40 985 titres (~140 020,88 $ US)
- Insiders
- KUMAR AMIT, Titterton Lewis H jr
- Total bought
- $140,021
- Total sold
- —
- Last activity
- 2026-07-31
- Last synced
-
2026-08-06 10:27:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-04
ANIX presents a genuine event-driven catalyst — insider cluster buys, a Zacks Strong Buy upgrade, international patent acceptances, and positive Phase 1/CAR-T clinical data — that warrants attention from a speculative…
The first sentence of the analysis written for ANIX on 2026-08-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 23.3% | 0.0% | 24.8% | |
| Ebit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2565.6% | |
| Ebitda Margin | 0.0% | 0.0% | -4706.7% | 0.0% | -2554.9% | |
| Operating Profit Margin | 0.0% | 0.0% | -5243.3% | 0.0% | -2565.6% | |
| Pretax Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -4728.6% | 0.0% | -2564.0% | |
| Net Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2528.6% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -4671.9% | 0.0% | -2530.1% | |
| Current Ratio | 8.077 | 8.545 | 12.503 | 14.826 | 28.349 | |
| Quick Ratio | 8.077 | 8.545 | 12.503 | 14.848 | 28.349 | |
| Solvency Ratio | -5.113 | -4.631 | -4.540 | -6.127 | -8.645 | |
| Cash Ratio | 0.632 | 0.508 | 0.451 | 6.068 | 22.936 | |
| Price To Earnings Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Forward Price To Earnings Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Earnings Diluted Ratio | -12.147 | -8.974 | -9.875 | -12.444 | -11.311 | |
| Price To Earnings Diluted Growth Ratio | 0.947 | -0.410 | 0.342 | 0.000 | 5.203 | |
| Price To Book Ratio | 8.841 | 5.583 | 4.023 | 5.856 | 4.105 | |
| Price To Sales Ratio | 0.000 | 0.000 | 466.175 | 0.000 | 284.114 | |
| Price To Free Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Price To Operating Cash Flow Ratio | -18.686 | -15.221 | -15.767 | -26.201 | -29.459 | |
| Debt To Assets Ratio | 0.013 | 0.011 | 0.007 | 0.007 | 0.007 | |
| Debt To Equity Ratio | 0.013 | 0.012 | 0.007 | 0.008 | 0.007 | |
| Debt To Capital Ratio | 0.013 | 0.011 | 0.007 | 0.008 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.061 | 1.080 | 1.049 | 1.047 | 1.023 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.008 | 0.000 | 0.024 | |
| Operating Cash Flow Ratio | -3.647 | -2.934 | -3.062 | -3.187 | -3.888 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -29.567 | 0.000 | -9.645 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -268.098 | 0.000 | 0.000 | -132.010 | -40,625.078 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -133.413 | -40,794.075 | |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -35.162 | -31.616 | -35.480 | -29.376 | -19.066 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -12.099 | -8.736 | -9.830 | -11.505 | -8.913 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-9.6% |
| Ebit Margin | 0.0% | 0.0% | ▲1458.8% |
| Ebitda Margin | 0.0% | 0.0% | ▲1452.3% |
| Operating Profit Margin | 0.0% | 0.0% | ▲1561.8% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲1458.5% |
| Net Profit Margin | 0.0% | 0.0% | ▲1440.1% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲1440.4% |
| Current Ratio | 8.077 | ▼-0.468 | ▼-6.383 |
| Quick Ratio | 8.077 | ▼-0.468 | ▼-6.388 |
| Solvency Ratio | -5.113 | ▼-0.482 | ▲0.698 |
| Cash Ratio | 0.632 | ▲0.124 | ▼-5.487 |
| Price To Earnings Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Forward Price To Earnings Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Earnings Diluted Ratio | -12.147 | ▼-3.173 | ▼-1.197 |
| Price To Earnings Diluted Growth Ratio | 0.948 | ▲1.358 | ▼-0.269 |
| Price To Book Ratio | 8.841 | ▲3.258 | ▲3.159 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-150.058 |
| Price To Free Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Price To Operating Cash Flow Ratio | -18.686 | ▼-3.466 | ▲2.381 |
| Debt To Assets Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Equity Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Debt To Capital Ratio | 0.013 | ▲0.002 | ▲0.004 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.061 | ▼-0.019 | ▲0.009 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.006 |
| Operating Cash Flow Ratio | -3.647 | ▼-0.713 | ▼-0.303 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲7.842 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | -268.098 | ▼-268.098 | ▲7936.939 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲8185.498 |
| Short Term Operating Cash Flow Coverage Ratio | -174.951 | ▼-174.951 | ▼-139.961 |
| Operating Cash Flow Coverage Ratio | -35.162 | ▼-3.545 | ▼-5.022 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -12.099 | ▼-3.364 | ▼-1.883 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $134.0M | $111.6M | $97.9M | $170.1M | $145.5M | |
| Enterprise value | $133.0M | $110.6M | $97.2M | $158.0M | $116.6M | |
| EV / Sales | 0.00x | 0.00x | 462.65x | 0.00x | 227.73x | |
| EV / Op. cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / Free cash flow | -18.54x | -15.08x | -15.65x | -24.33x | -23.61x | |
| EV / EBITDA | -12.10x | -8.74x | -9.83x | -11.51x | -8.91x | |
| Net debt / EBITDA | 0.10x | 0.08x | 0.07x | 0.88x | 2.21x | |
| Current ratio | 8.08x | 8.54x | 12.50x | 14.83x | 28.35x | |
| Income quality | 0.65x | 0.58x | 0.62x | 0.47x | 0.38x | |
| Graham net-net | $0 | $1 | $1 | $1 | $1 | |
| Tax burden | 99.1% | 98.9% | 98.8% | 98.7% | 98.6% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 99.9% | |
| Working capital | $13.9M | $18.9M | $23.3M | $28.2M | $34.7M | |
| Invested capital | $14.1M | $19.1M | $23.5M | $28.4M | $35.0M | |
| Return on assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Operating ROA | -62.1% | -58.7% | -39.4% | -41.6% | -57.5% | |
| Return on tangible assets | -68.0% | -58.1% | -38.4% | -44.7% | -35.7% | |
| Return on equity | -72.1% | -62.8% | -40.3% | -46.8% | -36.5% | |
| Return on invested capital | -82.7% | -72.3% | -46.8% | -48.8% | -37.5% | |
| Return on capital employed | -82.9% | -72.4% | -46.9% | -48.9% | -37.5% | |
| Earnings yield | -8.2% | -11.2% | -10.0% | -8.0% | -8.9% | |
| Free cash flow yield | -5.4% | -6.6% | -6.3% | -3.8% | -3.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 2995.7% | 0.0% | 1381.5% | |
| R&D / Sales | 0.0% | 0.0% | 2271.0% | 0.0% | 1208.9% | |
| Stock comp / Sales | 0.0% | 0.0% | 2105.7% | 0.0% | 1465.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 469d | 0d | 0d | |
| Days payables outstanding | 1673d | 0d | 467d | 0d | 129d | |
| Operating cycle | 0d | 0d | 469d | 0d | 0d | |
| Cash conversion cycle | -1673d | 0d | 2d | 0d | -129d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+20.1%EV / Sales n/aEV / EBITDA ▼-38.5%EV / Op. cash flow ▼-3.462Earnings yield ▲+0.031
Profitability
Return on equity ▼-0.093Return on assets ▼-0.098Return on invested capital ▼-0.103Return on capital employed ▼-0.105Operating ROA ▼-0.034Income quality ▲+0.073Tax burden ▲+0.002
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.468Net debt / EBITDA ▲+0.013Working capital ▼-4942000.000Invested capital ▼-4978000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-7.9%EV / Sales ▼-100.0%EV / EBITDA ▼-35.7%EV / Op. cash flow ▲+5.071Earnings yield ▲+0.007
Profitability
Return on equity ▼-0.355Return on assets ▼-0.322Return on invested capital ▼-0.452Return on capital employed ▼-0.454Operating ROA ▼-0.046Income quality ▲+0.274Tax burden ▲+0.005
Efficiency
Days sales outstanding n/aDays payables outstanding ▲+1543.982Operating cycle n/aCash conversion cycle ▼-1543.982Capex / Sales n/aR&D / Sales ▼-12.089
Balance-sheet strength
Current ratio ▼-20.272Net debt / EBITDA ▼-2.112Working capital ▼-20813449.000Invested capital ▼-20874404.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-22 Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here''s What You Should Know Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 2026-07-22 New Strong Buy Stocks for July 22nd HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 2026.
- 2026-07-14 Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology Notice of Acceptance marks first Australian patent covering Anixa''s breast cancer vaccine platform Continues expansion of global intellectual property coverage in markets with increasing breast cancer incidence rates SAN JOSE, Calif., July 14, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of Acceptance for a new patent related to Anixa''s breast cancer vaccine technology.
- 2026-07-06 Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the first patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T/CER-T therapy for recurrent ovarian cancer.
- 2026-06-29 Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 Composition of matter patent secures exclusive protection for Anixa''s breast cancer vaccine in South Korea through 2040, expanding the Company''s growing global IP estate Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and greater concentrations of younger breast cancer patients SAN JOSE, Calif., June 29, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued Patent Number 10-2960889 related to Anixa''s breast cancer vaccine technology.
- 2026-06-26 Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences'' Frontiers in Cancer Immunotherapy Symposium Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Ovarian cancer CAR-T therapy, lira-cel, presentation highlights positive survival observations from ongoing Phase 1 clinical trial Presentations highlight Anixa''s clinical progress and collaborations with leading cancer research institutions, including Cleveland Clinic and Moffitt Cancer Center SAN JOSE, Calif., June 26, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its two clinical-stage immunotherapy programs were presented at the New York Academy of Sciences'' Frontiers in Cancer Immunotherapy symposium this week.
- 2026-06-25 Here''s Why You Should Add ANIX Stock to Your Portfolio Now Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phase II study and expanding intellectual property protection.
- 2026-06-11 Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences'' Frontiers in Cancer Immunotherapy Symposium Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants Presentations highlight Anixa''s clinical progress and collaborations with leading cancer research institutions SAN JOSE, Calif., June 11, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its clinical-stage immunotherapy programs will be presented at the New York Academy of Sciences'' Frontiers in Cancer Immunotherapy symposium, being held June 22 – 23, 2026, at Memorial Sloan Kettering Cancer Center in New York City.
- 2026-06-01 Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer SAN JOSE, Calif., June 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa''s ovarian cancer vaccine technology.
- 2026-05-11 Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clinical trial featured in presentation at the International Society for Cell & Gene Therapy2026 Annual Meeting SAN JOSE, Calif., May 11, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company''s follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.